Suchergebnisse - "Hasselbalch, Hans Carl"

PubPharm (7)

1

Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

enthalten in: Leukemia & lymphoma | 2019

von Holmström, M. | Novotny, G. | Petersen, J. | +6

2

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

enthalten in: Expert review of hematology | 2017

von Bjørn, M. | Hasselbalch, H.

3

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

enthalten in: Leukemia research | 2013

von Stauffer Larsen, T. | Iversen, K. | Hansen, E. | +12

4

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

enthalten in: Hematology (Amsterdam, Netherlands) | 2009

von Larsen, T. | Møller, M. | de Stricker, K. | +6

5

Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence

enthalten in: Blood | 2008

von Lataillade, J. | Pierre-Louis, O. | Hasselbalch, H. | +5

6

Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia

enthalten in: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | 2007

von Stauffer Larsen, T. | Hasselbalch, H. | Pallisgaard, N. | +1

7

New molecular markers within the chronic myeloproliferative disorders. II : the JAK2 mutation

enthalten in: Ugeskrift for laeger | 2006

von Larsen, T. | Pallisgaard, N. | Christensen, J. | +4

1
[1]